Oncology Medications

Ukoniq™ 

(Umbralisib)

Ukoniq™ (Umbralisib) Is Available Exclusively From Onco360!

 

“UKONIQ is the first and only, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon. Accelerated approval was granted for these indications based on overall response rate (ORR) data from the Phase 2 UNITY-NHL Trial (NCT02793583). Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial. This application was granted priority review for the MZL indication. In addition, UKONIQ was granted Breakthrough Therapy Designation (BTD) for the treatment of MZL and orphan drug designation (ODD) for the treatment of MZL and FL.”1

UKONIQ™ is a kinase inhibitor indicated for the treatment of adult patients with: 

Dosage and Administration

Dosage Forms and Strengths1

UKONIQ is available in 200 mg tablets (NDC 73150-200-12). 

Community and hospital-based oncologists can immediately place prescription orders for UKONIQ, as well as other cancer and supportive care medications. 

Download the Official Press Release

How to Order

Call

Call 877-662-6633.

Fax

Download the Oral Rx
Oncology Order Form and
fax it to 877-662-6355.
Oral Order Form

e-prescribe

e-Prescribe to Onco360 in Louisville, KY 40223, or NPI# 1437577988 under the retail tab in your EMR/EHR or standalone e-prescribing application.

1 https://www.tgtherapeutics.com/
2 UKONIQ prescribing information: TG Therapeutics. UKONIQ trademark is owned or licensed by TG Therapeutics.